| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
License revenue | ||||||||||||
375 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
4,603 | 5,668 | 5,772 | 6,136 | 6,790 | 6,908 | 6,457 | 4,234 | 4,231 | 4,416 | 6,802 | 4,881 | 6,404 |
General and administrative | ||||||||||||
2,153 | 2,604 | 2,151 | 2,325 | 2,005 | 2,063 | 2,142 | 2,603 | 2,113 | 2,130 | 1,780 | 2,135 | 3,804 |
Total operating expenses | ||||||||||||
6,756 | 8,272 | 7,923 | 8,461 | 8,795 | 8,971 | 8,599 | 6,837 | 6,344 | 6,546 | 8,582 | 7,016 | 10,208 |
Loss from operations | ||||||||||||
-6,381 | -8,272 | -7,923 | -8,461 | -8,795 | -8,971 | -8,599 | -6,837 | -6,344 | -6,546 | -8,582 | -7,016 | -10,208 |
Interest income | ||||||||||||
68 | 32 | 80 | 119 | 82 | 120 | 128 | 122 | 77 | 31 | 40 | 49 | 50 |
Interest expense | ||||||||||||
12 | 2 | 5 | 9 | 7 | 1 | 4 | 8 | 6 | - | 21 | - | - |
Interest expense - related party | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 121 |
Australian research and development incentives | ||||||||||||
85 | 3 | -7 | 61 | 75 | -432 | 299 | 243 | 646 | -137 | 961 | 494 | 397 |
Foreign currency gains (loss) | ||||||||||||
-991 | 240 | -80 | -76 | 42 | -220 | -249 | -222 | -144 | -64 | 787 | -432 | 468 |
Change in fair value of warrant liability | ||||||||||||
- | - | - | - | - | -11,004 | -1,793 | 662 | 4,851 | - | - | - | - |
Net loss | ||||||||||||
-7,231 | - | - | - | -8,603 | - | - | - | - | - | - | - | - |
Net loss | ||||||||||||
-7,231 | - | - | - | -8,603 | - | - | - | - | -6,593 | -6,815 | -6,905 | -9,414 |
Net loss | ||||||||||||
- | - | -7,935 | -8,366 | - | 1,480 | -6,632 | -7,364 | -10,622 | - | - | - | - |
Dividend attributable to down round feature of warrants | ||||||||||||
303 | 0 | 0 | 0 | 359 | - | - | - | - | - | - | - | - |
Dividend attributable to Series A & B convertible preferred stock | ||||||||||||
372 | - | - | - | - | - | - | - | - | - | - | - | - |
Series A & B convertible preferred stock - beneficial conversion feature | ||||||||||||
9,399 | - | - | - | - | - | - | - | - | - | - | - | - |
Accretion of preferred stock to redemption value | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 244 |
Net loss attributable to common stockholders | ||||||||||||
-17,305 | -7,996 | -7,935 | -8,366 | -8,962 | 1,480 | -6,632 | -7,364 | -10,622 | -6,593 | -6,815 | -6,905 | -9,658 |
Net Loss Per Share | ||||||||||||
Basic (in dollars per share) | ||||||||||||
-0.55 | - | -0.33 | - | -0.47 | - | -0.45 | - | - | - | -0.73 | - | - |
Diluted (in dollars per share) | ||||||||||||
-0.55 | - | -0.33 | - | -0.47 | - | -0.55 | - | - | - | -0.73 | - | - |
Weighted Average Number of Shares Outstanding, Diluted [Abstract] | ||||||||||||
Basic (in shares) | ||||||||||||
31,632 | - | 23,923 | - | 19,237 | - | 14,701 | - | - | - | 9,395 | - | - |
Diluted (in shares) | ||||||||||||
31,632 | - | 23,923 | - | 19,237 | - | 15,211 | - | - | - | 9,395 | - | - |
Net loss per share - basic and diluted (in dollars per share) | ||||||||||||
- | - | - | -0.37 | - | - | - | -0.50 | -0.85 | - | - | -0.74 | -1.39 |
Weighted average common shares outstanding - basic and diluted (in shares) | ||||||||||||
- | - | - | 22,906 | - | - | - | 14,691 | 12,449 | - | - | 9,392 | 6,945 |